Climb Bio Inc (CLYM) - Total Liabilities
Based on the latest financial reports, Climb Bio Inc (CLYM) has total liabilities worth $7.27 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CLYM cash flow metrics to assess how effectively this company generates cash.
Climb Bio Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Climb Bio Inc's total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Climb Bio Inc's assets to evaluate the company's liquid asset resilience ratio.
Climb Bio Inc Competitors by Total Liabilities
The table below lists competitors of Climb Bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Beijing Hanbang Technology Corp
SHE:300449
|
China | CN¥157.86 Million |
|
Yunnan luoping Zinc & Electricity Co Ltd
SHE:002114
|
China | CN¥1.40 Billion |
|
Angel Oak Financial Strategies Income Term Trust
NYSE:FINS
|
USA | $127.39 Million |
|
TaiMed Biologics
TWO:4147
|
Taiwan | NT$896.74 Million |
|
Cable One Inc
NYSE:CABO
|
USA | $4.15 Billion |
|
Meihua International Medical Technologies Co Ltd
NASDAQ:MHUA
|
USA | $25.64 Million |
|
J.Kumar Infraprojects Limited
NSE:JKIL
|
India | Rs30.75 Billion |
|
Xinjiang Talimu Agriculture Development Co Ltd
SHG:600359
|
China | CN¥839.80 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Climb Bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Climb Bio Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Climb Bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Climb Bio Inc (2019–2025)
The table below shows the annual total liabilities of Climb Bio Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.27 Million | +37.00% |
| 2024-12-31 | $5.31 Million | +84.88% |
| 2023-12-31 | $2.87 Million | -54.28% |
| 2022-12-31 | $6.28 Million | +3.96% |
| 2021-12-31 | $6.04 Million | +97.13% |
| 2020-12-31 | $3.06 Million | +291.19% |
| 2019-12-31 | $783.00K | -- |
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies for immune-mediated diseases. The company develops budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug IV for the treatment of primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. In addition, the co… Read more